Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
European Journal of Cancer2017Vol. 88, pp. 38–47
Citations Over TimeTop 1% of 2017 papers
Mélodie Tazdait, Laura Mezquita, J. Lahmar, Roberto Ferrara, François Bidault, Samy Ammari, Corinne Balleyguier, David Planchard, Anas Gazzah, Jean‐Charles Soria, Aurélien Marabelle, Benjamin Besse, Caroline Caramella
Related Papers
- → Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma(2011)272 cited
- → Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib(2010)29 cited
- → The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms(2018)9 cited
- → Comparison of response evaluation criteria in solid tumors (RECIST), European Association for the study of the liver (EASL) and modified RECIST criteria in evaluation of tumor response after transarteriai chemoembolization of primary liver cancer(2011)2 cited
- → Application of circulating tumor cells detection in chemotherapeutic efficacy evaluation of non-small cell lung cancer(2018)